Recruiting
Systemic scleroderma+4
RecruitingA long-term safety study of KYV-101 in patients previously treated for lupus nephritis, systemic sclerosis, myasthenia gravis, rheumatoid arthritis, or stiff person syndrome
InvestigationalNo placebo
A long-term safety study of KYV-101 in patients previously treated for lupus nephritis, systemic sclerosis, myasthenia gravis, rheumatoid arthritis, or stiff person syndrome
InvestigationalNo placebo
- Disease:Systemic sclerodermaMyasthenia gravis+3
- Substances:KYV-101
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:KYV-101
- Sponsor:Kyverna Therapeutics Inc.